Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2019 | Story Valentino Ndaba | Photo Charl Devenish
Coloquium read more
The iKUDU kick-off meeting sets the tone for a three-year collaboration between 10 universities that share a vision for internationalisation

In order for higher education institutions to stay truly relevant and impactful, they need to be able to respond to global trends and patterns of higher education and internationalisation. Digitisation is one of the critical aspects of 4IR, which is currently unfolding.

The iKudu project is an innovative project that will connect large numbers of students utilising digital technology, thereby allowing students to gain international exposure irrespective of socioeconomic background, gender or disability status. Internationalised and transformed curricula, which integrate Cooperative Online International Learning (COIL) and virtual exchange, are a new model for the higher education teaching and learning. This will allow all students to develop the graduate attributes required for success and employability in a globalised world.

The University of the Free State (UFS) is the coordinator of the iKUDU project, which has been awarded €999 881,00 funding from the European Union’s Erasmus + Capacity Building in Higher Education (CBHE) framework. It held its kick-off meeting from 25 to 26 November 2019 at the Bloemfontein Campus. The Office for International Affairs coordinates the project and hosted this meeting, which mapped out the project’s trajectory for the next three years. The co-coordinating University of Antwerp and all partner universities attended.

Inclusive and decolonised curricula

Over the next three years 10 partner consortium universities, consisting of five European partner universities and five South African partner universities, will have the responsibility of developing a contextualised South African concept of Internationalisation of the Curriculum (IoC), which integrates COIL virtual exchanges. This is an ideal firmly anchored in our university’s Integrated Transformation Plan (ITP).

Dr Jos Beelen, a professor of Global Learning at The Hague University of Applied Sciences in The Netherlands, referred in his keynote address to the 2014 Erasmus Impact Study, which assessed the effects of mobility on the skills and employability of students and the internationalisation of higher education institutions.

According to the findings, 64% of employers considered international experience important for recruitment which was a significant increase from 37% in 2006. In addition, the study showed that 64% of employers said graduates with an international background are given greater professional responsibility. Although conducted in Brussels in the European Union, the results reflect the growing view that internationalisation is the future.

Bridging the mobility gap

COIL Consulting Director, Jon Rubin, also presented a keynote address in which he stated: “International education has long suggested that the way to expand one’s view of other cultures is to travel, usually by studying abroad, and that modality, when engaged with intensity and self-reflection, is probably still the best way for students to learn about the world.”

Coloquium Content
Delegates who attended the iKUDU Colloquium at the University of the Free State ( Photo: Charl Devenish) 

However, only a select few university students and professors have the chance to blend study and research with travel. “COIL is a method for re-purposing the tools and affordances of online education so that they serve a new goal – that of providing meaningful international experiences for students and instructors. I think we can do more to build true online bridges to other cultures and I believe we can accomplish that through COIL linkages,” said Rubin.

UFS Rector and Vice-Chancellor, Prof Francis Petersen, alluded to the project in his welcoming speech saying: “The focus of the iKUDU project is curriculum transformation.” The iKUDU kick-off meeting served as a platform to develop a project implementation plan that will ensure that equal, bilateral international collaboration between institutions and in the classroom remains a high priority.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept